Ulcerative Colitis Apriso,Asacol HD and Lialda Forecast and Market Analysis to 2022

Researchmoz presents this most up-to-date research on"Ulcerative Colitis Apriso,Asacol HD and Lialda Forecast and Market Analysis to 2022". The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

Apriso (Ulcerative Colitis) - Forecast and Market Analysis to 2022 http://www.researchmoz.us/apriso-ulcerative-colitis-forecast-and-market-analysis-to-2022-report.html

Apriso features an Intellicor-coated gel suspension of mesalamine. The Intellicor coating that enables the release of mesalamine exclusively in the colon, dissolving at pH =6. Therefore, the entire mesalamine concentration of the pill formulation is successfully administered to the colon, unlike a conventional mesalamine formulation, which would be partly depleted in the acidic environment of the stomach or mostly absorbed in the jejunum (the middle portion of the small intestine that connects the duodenum and the ileum, which are not part of the colon).

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

For Reports On Healthcare Visit @ http://www.researchmoz.us/healthcare-market-reports-56.html

Scope

Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Apriso including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Apriso for the top six countries from 2012 to 2022.

Sales information covered for the US, Germany, Spain, the UK, China and India.

Asacol HD (Ulcerative Colitis) - Forecast and Market Analysis to 2022 http://www.researchmoz.us/asacol-hd-ulcerative-colitis-forecast-and-market-analysis-to-2022-report.html

Asacol made a significant impact in the UC market, mostly thanks to mesalamines well-known safety profile. In turn, Asacol is considered the gold standard for mesalamine products in all forms (tablets, suppositories, enemas). The active ingredient in Asacol, mesalamine, exerts its function through its anti-inflammatory and immunosuppressive actions as a COX inhibitor, a blocker of T-cell-activating cytokines, an adenosine inducer, and an antibody synthesis inhibitor.During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on Asacol including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for Asacol for the top ten countries from 2012 to 2022.Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China, India, and Canada.

Lialda (Ulcerative Colitis) - Forecast and Market Analysis to 2022 http://www.researchmoz.us/lialda-ulcerative-colitis-forecast-and-market-analysis-to-2022-report.html

Lialda is a patented multi-matrix (MMX)-release, coated formulation of mesalamine that can be taken once or twice daily. Clinical trials have demonstrated the efficacy of this agent over placebo for the induction and maintenance of remission in UC. Upon exposure to the alkaline pH of the colon, the MMX coating dissolves and reveals the gel suspension of mesalamine, which is concomitantly diffused within the intestinal fluid.During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Scope

• Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Lialda including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Lialda for the top seven countries from 2012 to 2022.
• Sales information covered for the US, Germany, Italy, Spain, the UK, Japan and Canada.

For More Information Kindly Contact:
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
Blog: http://globalandchinamarket.blogspot.com